ERBB2 and breast carcinoma: On the basis of these intriguing results, palbociclib received the FDA-accelerated approval for luminal HER2 negative breast cancer, both as an initial endocrine-based therapy for metastatic breast cancer and in combination with fulvestrant after progression, following an endocrine therapy for advanced breast cancer.